PSMD1 Identified as a Key Therapeutic Target in Multiple Myeloma

We're excited to share our contribution to a new study published in Blood identifying PSMD1 as a promising therapeutic target in multiple myeloma (MM)!

The study, led by the Anderson Lab at Dana-Farber with contributions from Filip Garbicz and Dr. Carrasco, shows that PSMD1 — a subunit of the 19S proteasome regulatory particle — is overexpressed in MM and associated with poor prognosis. Knocking down PSMD1 impaired cancer cell viability, triggered accumulation of polyubiquitinated proteins, and induced apoptosis. Critically, PSMD1-targeting siRNA delivered via lipid nanoparticles reduced tumor growth in cell lines and primary patient samples while sparing normal cells, overcame proteasome inhibitor resistance, and extended survival in xenograft models. The findings point to PSMD1 as a broadly relevant cancer target with implications for immune modulation and drug resistance.